Cholesterol Treatment Trialists’ Collaboration,Christina Reith,David Preiss,Lisa Blackwell,Jonathan Emberson,Enti Spata,Kelly Davies,Heather Halls,Lisa Holland,Kate Wilson,Alistair J Roddick,Christopher P Cannon,Robert Clarke,Helen M Colhoun,Paul N Durrington,Shinya Goto,Graham A Hitman,G Kees Hovingh,J Wouter Jukema,Wolfgang Koenig,Ian Marschner,Borislava Mihaylova,Connie Newman,Jeffrey L Probsfield,Paul M Ridker,Marc S Sabatine,Naveed Sattar,Gregory G Schwartz,Luigi Tavazzi,Andrew Tonkin,Stella Trompet,Harvey White,Salim Yusuf,Jane Armitage,Anthony Keech,John Simes,Rory Collins,Colin Baigent,Elizabeth Barnes,Jordan Fulcher,William G Herrington,Adrienne Kirby,Rachel O'Connell,Pierre Amarenco,Hiroyuki Arashi,Philip Barter,D John Betteridge,Michael Blazing,Gerard J Blauw,Jackie Bosch,Louise Bowman,Eugene Braunwald,Richard Bulbulia,Robert Byington,Michael Clearfield,Stuart Cobbe,Björn Dahlöf,Barry Davis,James de Lemos,John R Downs,Bengt Fellström,Marcus Flather,Ian Ford,Maria Grazia Franzosi,John Fuller,Curt Furberg,Robert Glynn,Uri Goldbourt,David Gordon,Antonio Gotto,Richard Grimm,Ajay Gupta,Harper Charlie,C Morton Hawkins,Richard Haynes,Hallvard Holdaas,Jemma Hopewell,Alan Jardine,John JP Kastelein,Sharon Kean,Patricia Kearney,George Kitas,John Kjekshus,Genell Knatterud,Robert H Knopp,Michael Koren,Vera Krane,Martin Landray,John LaRosa,Roberto Latini,Eva Lonn,Donata Lucci,Jean MacFadyen,Peter Macfarlane,Stephen MacMahon,Aldo Maggioni,Roberto Marchioli,Lemuel Moyé,Sabina Murphy,Andrew Neil,Enrico B Nicolis,Chris Packard,Sarah Parish,Terje R Pedersen,Richard Peto,Marc Pfeffer,Neil Poulter,Sara Pressel,Jeffrey Probstfield,Mahboob Rahman,Michele Robertson,Frank Sacks,Roland Schmieder,Patrick Serruys,Peter Sever,John Shaw,James Shepherd,Lara Simpson,Peter Sleight,Liam Smeeth,Jonathan Tobert,Gianni Tognoni,John Varigos,Christoph Wanner,Hans Wedel,Stephen Weis,K Michael Welch,John Wikstrand,Lars Wilhelmsen,Stephen Wiviott,Junichi Yamaguchi,Robin Young,Faiez Zannad

Abstract:BACKGROUND: Previous meta-analyses of summary data from randomised controlled trials have shown that statin therapy increases the risk of diabetes, but less is known about the size or timing of this effect, or who is at greatest risk. We aimed to address these gaps in knowledge through analysis of individual participant data from large, long-term, randomised, double-blind trials of statin therapy.METHODS: We conducted a meta-analysis of individual participant data from randomised controlled trials of statin therapy that participated in the CTT Collaboration. All double-blind randomised controlled trials of statin therapy of at least 2 years' scheduled duration and with at least 1000 participants were eligible for inclusion in this meta-analysis. All recorded diabetes-related adverse events, treatments, and measures of glycaemia were sought from eligible trials. Meta-analyses assessed the effects of allocation to statin therapy on new-onset diabetes (defined by diabetes-related adverse events, use of new glucose-lowering medications, glucose concentrations, or HbA1c values) and on worsening glycaemia in people with diabetes (defined by complications of glucose control, increased use of glucose-lowering medication, or HbA1c increase of ≥0·5%). Standard inverse-variance-weighted meta-analyses of the effects on these outcomes were conducted according to a prespecified protocol.FINDINGS: Of the trials participating in the CTT Collaboration, 19 trials compared statin versus placebo (123 940 participants, 25 701 [21%] with diabetes; median follow-up of 4·3 years), and four trials compared more versus less intensive statin therapy (30 724 participants, 5340 [17%] with diabetes, median follow-up of 4·9 years). Compared with placebo, allocation to low-intensity or moderate-intensity statin therapy resulted in a 10% proportional increase in new-onset diabetes (2420 of 39 179 participants assigned to receive a statin [1·3% per year] vs 2214 of 39 266 participants assigned to receive placebo [1·2% per year]; rate ratio [RR] 1·10, 95% CI 1·04-1·16), and allocation to high-intensity statin therapy resulted in a 36% proportional increase (1221 of 9935 participants assigned to receive a statin [4·8% per year] vs 905 of 9859 participants assigned to receive placebo [3·5% per year]; 1·36, 1·25-1·48). For each trial, the rate of new-onset diabetes among participants allocated to receive placebo depended mostly on the proportion of participants who had at least one follow-up HbA1c measurement; this proportion was much higher in the high-intensity than the low-intensity or moderate-intensity trials. Consequently, the main determinant of the magnitude of the absolute excesses in the two types of trial was the extent of HbA1c measurement rather than the proportional increase in risk associated with statin therapy. In participants without baseline diabetes, mean glucose increased by 0·04 mmol/L with both low-intensity or moderate-intensity (95% CI 0·03-0·05) and high-intensity statins (0·02-0·06), and mean HbA1c increased by 0·06% (0·00-0·12) with low-intensity or moderate-intensity statins and 0·08% (0·07-0·09) with high-intensity statins. Among those with a baseline measure of glycaemia, approximately 62% of new-onset diabetes cases were among participants who were already in the top quarter of the baseline distribution. The relative effects of statin therapy on new-onset diabetes were similar among different types of participants and over time. Among participants with baseline diabetes, the RRs for worsening glycaemia were 1·10 (1·06-1·14) for low-intensity or moderate-intensity statin therapy and 1·24 (1·06-1·44) for high-intensity statin therapy compared with placebo.INTERPRETATION: Statins cause a moderate dose-dependent increase in new diagnoses of diabetes that is consistent with a small upwards shift in glycaemia, with the majority of new diagnoses of diabetes occurring in people with baseline glycaemic markers that are close to the diagnostic threshold for diabetes. Importantly, however, any theoretical adverse effects of statins on cardiovascular risk that might arise from these small increases in glycaemia (or, indeed, from any other mechanism) are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials. These findings should further inform clinical guidelines regarding clinical management of people taking statin therapy.FUNDING: British Heart Foundation, UK Medical Research Council, and Australian National Health and Medical Research Council.

Inhibition of neutrophil‐endothelial cell adhesion by a neutrophil product, cathepsin G

Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

Pitavastatin is Well-Tolerated with no Detrimental Effects on Physical Function

Pitavastatin in the Prevention of Cardiovascular Disease in People Living with HIV: A Review

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

Prevention and treatment of cardiovascular disease in HIV: practical insights in an evolving field

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV

LTE-advanced carrier aggregation supporting fully standard 3GPP MIMO by optical polarization multiplexing

Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study

WISP1 overexpression promotes proliferation and migration of human vascular smooth muscle cells via AKT signaling pathway.

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection

A recent origin of marmots.

The Effect of Pitavastatin on Blood Glucose and Its Efficacy in Diabetic Patients with Hypercholesterolemia

Examining Incidence of Diabetes in People Living with HIV: Tracking the Shift in Traditional and HIV-related Risk Factors

A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system

Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications

Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial

Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials